Search

Your search keyword '"Edzard, Schwedhelm"' showing total 297 results

Search Constraints

Start Over You searched for: Author "Edzard, Schwedhelm" Remove constraint Author: "Edzard, Schwedhelm"
297 results on '"Edzard, Schwedhelm"'

Search Results

201. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study

202. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency

203. Development of nonfibrotic left ventricular hypertrophy in an ANG II-induced chronic ovine hypertension model

204. Pharmacokinetic of 3H-deacetylasperulosidic acid in mice

205. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension

206. A comparison of the association between glomerular filtration and L-arginine status in HIV-infected and uninfected African men: the SAfrEIC study

207. P4‐056: Cerebrospinal fluid L‐arginine and symmetrical dimethylarginine are associated with increased soluble amyloid precursor protein beta production in Alzheimer's disease

208. Urinary F2-isoprostanes, a biomarker of lipid peroxidation, independently correlate with survival in a multicenter prospective cohort of incident pulmonary arterial hypertension

209. Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort

210. CLA does not impair endothelial function and decreases body weight as compared with safflower oil in overweight and obese male subjects

211. The role of asymmetric and symmetric dimethylarginines in renal disease

212. Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function

213. Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study

214. Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischaemic stroke due to a ceiling effect of enzymatic activity in brain

215. Association of Plasma ADMA Levels with MRI Markers of Vascular Brain Injury: The Framingham Offspring Study

216. Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke

217. Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography–Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort

218. Association of the Endogenous Nitric Oxide Synthase Inhibitor ADMA with Carotid Artery Intimal Media Thickness in the Framingham Heart Study Offspring Cohort

219. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk

220. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria

221. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke

222. L-Arginine enhances the triglyceride-lowering effect of simvastatin in patients with elevated plasma triglycerides

223. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study

224. Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension

225. Quantification of arginine and its mono- and dimethylated analogs NMMA, ADMA and SDMA in biological fluids by LC-MS/MS: Is LC superfluous?

226. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis

227. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study

228. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease

229. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

230. Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia

231. P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease

232. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism

233. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension

234. Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients

235. Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension

236. Is the malononitrilamide FK778 better for prevention of acute or chronic rejection?

237. Influence of a perioperative ω-3 fatty acid infusion on prostanoid metabolism during CPB cardiac surgery

238. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome

239. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma

240. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral L-arginine

241. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study

242. Efficacy study of FK778, tacrolimus and sirolimus to prevent posttransplant obliterative airway disease

244. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study

245. Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis

246. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality

247. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects

248. Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia

249. Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction

250. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma

Catalog

Books, media, physical & digital resources